- Coordinator
- Eberhard Karls Universitaet Tuebingen, Germany
- Runs
- 1 October 2023 to 30 September 2027
- Status
- Running
- EU funding
- €2.2m
- Total cost
- —
- Partners
- 23 organisations in 8 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101120256
What the project is doing
In the project's own words, from its summary on CORDIS.
Modern medicine seeks to personalize diagnosis and treatment to the needs of individual patients. This need is heightened in particular for those individual patients where no treatments are available – and where current standard treatment development paradigms exclude to generate such. The ultimate goal of Medicine made to Measure (MMM) is to go even beyond the latest genetic medicine approaches, implementing a novel paradigm of treatment development: the field of single patient tailored antisense oligonucleotide (ASO) treatments for patients with nano-rare disease mutations.
Specifically, MMM will develop core modules of a novel “out-of-the-box”, but still EMA-advised treatment development path for these patients - from omics-based theranostics, via preclinical target validation to innovative trial methodology and a pioneering ethical framework for individualised genetic therapies. MMM provides a unique opportunity for doctoral candidates to be involved in building - and to receive training - in all core modules needed for tailored ASO treatment in Europe.
This new scientific field requires a new generation of open-minded, technology-fluent and applications-oriented experts. MMM will help educate future drug development and translational experts in adopting and disseminating such a cross-specialty approach. Our idea for this innovative training network is built on our personal experience and understanding of the importance of single patient tailored genetic treatments in the years to come.
We propose a consortium of world-leading experts and partners that present with extended experience and relevant know-how in molecular biology, neurology, translational medicine, biochemistry, bioinformatics, philosophy, mathematics, regulatory science and engineering. Thus, MMM provides an exceptional platform to young, ambitious and talented researchers who like to engage in supporting the concept of single patient tailored treatments.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Eberhard Karls Universitaet Tuebingen | Tuebingen | Germany | Coordinator |
| Bianogmp GmbH | Gera | Germany | Participant |
| Cegat GmbH | Tubingen | Germany | Associatedpartner |
| Fitt - Institut Fur Technologietransfer an Der Hochschule Fur Technikund Wirtschaft Des Saarlandes Gemeinnutzige GmbH | Saarbrucken | Germany | Associatedpartner |
| Grasshopper Films GbR | Tübingen | Germany | Associatedpartner |
| Ludwig-Maximilians-Universitaet Muenchen | Planegg | Germany | Participant |
| NMI Technologietransfer GmbH | Reutlingen | Germany | Associatedpartner |
| Technische Universitaet Ilmenau | Ilmenau | Germany | Associatedpartner |
| Universitaetsklinikum Essen | Essen | Germany | Associatedpartner |
| Universitatsklinikum Heidelberg | Heidelberg | Germany | Participant |
| XNApharma GmbH | Gera | Germany | Associatedpartner |
| Eurordis - Rare Diseases Europe | Paris | France | Associatedpartner |
| Biotalentum Tudasfejleszto Kft | Goedoello | Hungary | Participant |
| Magyar Agrar- Es Elettudomanyi Egyetem | Godollo | Hungary | Associatedpartner |
| Alma Mater Studiorum - Universita Di Bologna | Bologna | Italy | Associatedpartner |
| Mhealth Technologies SRL | Bologna | Italy | Participant |
| Academisch Ziekenhuis Leiden | Leiden | Netherlands | Participant |
| Agentschap College Ter Beoordeling Van Geneesmiddelen | Utrecht | Netherlands | Associatedpartner |
| Charles River Laboratoiries Den Bosch BV | 'S-Hertogenbosch | Netherlands | Associatedpartner |
| Astrazeneca AB | Sodertaelje | Sweden | Associatedpartner |
| Uppsala Universitet | Uppsala | Sweden | Participant |
| The Chancellor Masters and Scholars of the University of Cambridge | Cambridge | United Kingdom | Associatedpartner |
| N=1 Collaborative, Inc. | Boston | United States | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI